KRSNAA

Krsnaa Diagnostics Share Price

₹935.70 +1.2 (0.13%)

21 Nov, 2024 14:39

SIP TrendupStart SIP in KRSNAA

Start SIP

Performance

  • Low
  • ₹915
  • High
  • ₹943
  • 52 Week Low
  • ₹528
  • 52 Week High
  • ₹973
  • Open Price₹940
  • Previous Close₹935
  • Volume56,323

Investment Returns

  • Over 1 Month + 13.06%
  • Over 3 Month + 28.72%
  • Over 6 Month + 56.16%
  • Over 1 Year + 48.52%
SIP Lightning

Smart Investing Starts Here Start SIP with Krsnaa Diagnostics for Steady Growth!

Invest Now

Krsnaa Diagnostics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 43.6
  • PEG Ratio
  • 2.2
  • Market Cap Cr
  • 3,021
  • P/B Ratio
  • 3.7
  • Average True Range
  • 37.42
  • EPS
  • 21.44
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 26.56
  • RSI
  • 61.38
  • MFI
  • 73.5

Krsnaa Diagnostics Financials

Krsnaa Diagnostics Technicals

EMA & SMA

Current Price
₹935.70
+ 1.2 (0.13%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹900.72
  • 50 Day
  • ₹851.09
  • 100 Day
  • ₹791.43
  • 200 Day
  • ₹729.58

Resistance and Support

934.67 Pivot Speed
  • R3 960.53
  • R2 951.97
  • R1 943.23
  • S1 925.93
  • S2 917.37
  • S3 908.63

What's your outlook on Krsnaa Diagnostics?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Krsnaa Diagnostics Ltd. is a leading provider of diagnostic and imaging services in India, specializing in radiology, pathology, and health check-ups. The company focuses on delivering high-quality, affordable healthcare solutions, enhancing patient access to diagnostic services across various regions.

Krsnaa Diagnostics has an operating revenue of Rs. 681.18 Cr. on a trailing 12-month basis. An annual revenue growth of 26% is outstanding, Pre-tax margin of 11% is healthy, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 9% and 34% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 50 which is a POOR score indicating inconsistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 31 indicates it belongs to a strong industry group of Medical-Services and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Krsnaa Diagnostics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-08-06 Quarterly Results
2024-05-18 Audited Results & Final Dividend
2024-02-12 Quarterly Results
2023-11-03 Quarterly Results
Date Purpose Remarks
2024-09-13 FINAL Rs.2.50 per share(50%)Final Dividend
2022-09-16 FINAL Rs.2.50 per share(50%)Final Dividend

Krsnaa Diagnostics F&O

Krsnaa Diagnostics Shareholding Pattern

27.17%
11.56%
2.86%
3.63%
0%
28.41%
26.37%

About Krsnaa Diagnostics

  • NSE Symbol
  • KRSNAA
  • BSE Symbol
  • 543328
  • ISIN
  • INE08LI01020

Similar Stocks to Krsnaa Diagnostics

Krsnaa Diagnostics FAQs

Krsnaa Diagnostics share price is ₹935 As on 21 November, 2024 | 14:25

The Market Cap of Krsnaa Diagnostics is ₹3021.4 Cr As on 21 November, 2024 | 14:25

The P/E ratio of Krsnaa Diagnostics is 43.6 As on 21 November, 2024 | 14:25

The PB ratio of Krsnaa Diagnostics is 3.7 As on 21 November, 2024 | 14:25

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23